Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2025The International Journal of NeuropsychopharmacologyOpen Access

Pharmacogenetic-Supported Prescribing for Kids With Mental Health Condtions

View Full Paper
Ask AI
Bookmark
Share

Authors

CBChad A. Bousman

Discussion

Loading...

Member takes

Overview

Mirror image trial shows PGx testing reduces symptoms in young individuals, suggesting safer medication choices.

Key Points

  • PGx testing improved symptoms and reduced adverse effects in youth with mental health conditions.
  • Overall, 82% of participants had actionable genetic results impacting their medication choices.
  • Data was collected prospectively for six months after PGx testing and retrospectively for the previous six months.
  • These findings support the integration of pharmacogenetic testing to enhance psychiatric treatment options for youth.

Cite This Study

Chad A. Bousman (2025) studied this question.

synapsesocial.com/papers/68af2ee5cf1dd9ea359e6790https://doi.org/10.1093/ijnp/pyaf052.371
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1177. A GENETICALLY INFORMED APPROACH TO ANTIDEPRESSANT PRESCRIPTION FOR YOUTH WITH MAJOR DEPRESSIVE DISORDER2025
  2. 2Pharmacogenetic Testing of Children and Adolescents with Mental Health Conditions: Real-World Experiences2025
  3. 3Real‐World Characterization of Psychiatric Pharmacogenomic Test Ordering and Clinical Relevance in Adults and Children2025
  4. 4641. AN OVERVIEW OF THE PROJECT EXPLORING GENE-DRUG PAIRS IN DOSE GUIDANCE OF ANTIDEPRESSANTS AND ANTIPSYCHOTICS2025
  5. 5Key informant perspectives on pharmacogenomic (PGx) testing for antidepressant prescribing in primary care in Ontario, Canada: a qualitative description study2025